GHAPPcast: The Clinical Utility of Guselkumab in UC

Thank you Johnson & Johnson for your support of this GHAPPcast episode.

Join us for a compelling episode of GHAPPcast, the official podcast for advanced practice providers in gastroenterology and hepatology. In this episode, host Gabriella McCarty, NP-C, welcomes esteemed guest Sharon Dudley-Brown, PhD, a leading expert from Johns Hopkins and a professor at the University of Delaware. Together, they dive deep into the clinical role of guselkumab, a newly approved IL-23 inhibitor for ulcerative colitis (UC).

This discussion unpacks the mechanism of action, efficacy, safety profile, and potential patient candidates for this innovative therapy. Sharon provides expert insights on how guselkumab compares to other biologics and small molecules, its advantages in targeting the IL-23 pathway, and the latest clinical trial data supporting its use. The episode also covers key considerations for patient selection, dosing flexibility, and the evolving role of combination therapy in inflammatory bowel disease (IBD) management.

Whether you’re a healthcare provider looking to optimize UC treatment strategies or seeking clarity on the latest biologic advancements, this episode offers practical takeaways to enhance your clinical decision-making.

Tune in now to stay ahead in the evolving landscape of ulcerative colitis treatments!

Subscribe to GHAPPcast on your favorite podcast platform and visit GHAPP.org for more expert-led education in gastroenterology and hepatology. Download the GHAPP ACE app to continue watching expert-led educational modules in gastroenterology and hepatology.